Neurocrine Biosciences Inc vs Twist Bioscience Corp — how do they compare? Neurocrine Biosciences Inc trades at $151.61 (market cap $16.46B), while Twist Bioscience Corp trades at $123 (market cap $7.72B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.1× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | TWST | |
|---|---|---|
Market Cap | $16.46B | $7.72B |
Sector | Health | Health |
52-Week High | $185.50 | $124.88 |
52-Week Low | $123.10 | $24.16 |
Enterprise Value | $16.48B | $7.65B |
Trailing returns across standard periods
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →